## FORM 4

## **UNITED STATES SE**

Washington, D.C. 20549

CURITIES AND EXCHANGE COMMISSIO
---------------------------------

OMB APPROVAL								
OMB Number:	3235-028							
Estimated average b	ourden							

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

Instruction 1(b).

Check this box to indicate that a
transaction was made pursuant to a
contract, instruction or written plan for
the purchase or sale of equity
securities of the issuer that is intended
to satisfy the affirmative defense
conditions of Rule 10b5-1(c). See
Instruction 10.

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Fritz Frederick J.</u>				2. Issuer Name and Ticker or Trading Symbol Imunon, Inc. [ IMNN ]						(Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  University Director 10% Owner				
(Last) (First) (Middle) C/O IMUNON, INC.				3. Date of Earliest Transaction (Month/Day/Year) 09/10/2024							Officer below)	(give title	Other (s below)	specify	
997 LENOX DRIVE, SUITE 100				ŀ	If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable				
(Street) LAWRENCEVILLE NJ 08648									Line						
(City)	(5	tate)	(Zip)								<u> </u>				
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
1. Title of Security (Instr. 3)  2. Transa Date (Month/D					Execution Date,		3. Transaction Code (Instr. 8)  4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4) 5)			5. Amoun Securities Beneficia Owned Fo	s Fe lly (E ollowing (I)	orm: Direct 0) or Indirect ) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
							Code V	Amount	(A) or (D)	Price	Reported Transacti (Instr. 3 a	on(s)		Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	cise (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/Y	Cod	saction e (Instr.	Derivative I		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Securi (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Cod	de V (A) (D)		Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)			
Stock Option (Right to Buy)	\$1.04 <sup>(1)</sup>	09/06/2024		А		6,737 <sup>(3)</sup>		09/06/2024 <sup>(2)</sup>	09/06/2034	Common Stock	6,737	\$0	32,070	D	

## Explanation of Responses:

- 1. Represents the closing price of Imunon, Inc. Common Stock on the date of grant.
- 2. The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant.
- 3. Option granted in lieu of cash for portion of board fees.

/s/ Kimberly Graper, VP of Finance & Controller

09/10/2024

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.